[go: up one dir, main page]

MX2013014518A - Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio. - Google Patents

Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.

Info

Publication number
MX2013014518A
MX2013014518A MX2013014518A MX2013014518A MX2013014518A MX 2013014518 A MX2013014518 A MX 2013014518A MX 2013014518 A MX2013014518 A MX 2013014518A MX 2013014518 A MX2013014518 A MX 2013014518A MX 2013014518 A MX2013014518 A MX 2013014518A
Authority
MX
Mexico
Prior art keywords
treating
reducing
controlling
inflammatory pain
compositions
Prior art date
Application number
MX2013014518A
Other languages
English (en)
Inventor
Keith Wayne Ward
Jinzhong Zhang
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of MX2013014518A publication Critical patent/MX2013014518A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición para tratar, controlar, reducir o mejorar el dolor inflamatorio, que comprende un agonista del receptor de glucocorticoide disociado ("DIGRA"), un profármaco del mismo, una sal farmacéuticamente aceptable del mismo, o un éster farmacéuticamente aceptable del mismo. La composición puede comprender un agente anti-inflamatorio adicional y puede ser formulada para la aplicación tópica, inyección o implantación. Esta puede ser utilizada en métodos de manejo del dolor ocular post-quirúrgico tal que éste tiene menor riesgo de provocar efectos colaterales adversos observados con otros agentes terapéuticos.
MX2013014518A 2011-06-07 2012-05-17 Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio. MX2013014518A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494137P 2011-06-07 2011-06-07
US13/467,080 US20120316199A1 (en) 2011-06-07 2012-05-09 Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
PCT/US2012/038368 WO2012170175A1 (en) 2011-06-07 2012-05-17 Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain

Publications (1)

Publication Number Publication Date
MX2013014518A true MX2013014518A (es) 2014-01-31

Family

ID=47293674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014518A MX2013014518A (es) 2011-06-07 2012-05-17 Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.

Country Status (8)

Country Link
US (1) US20120316199A1 (es)
KR (1) KR20140035481A (es)
AR (1) AR086686A1 (es)
AU (1) AU2012268692A1 (es)
CA (1) CA2838876A1 (es)
MX (1) MX2013014518A (es)
TW (1) TW201300378A (es)
WO (1) WO2012170175A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
JP2020536955A (ja) 2017-10-06 2020-12-17 ファウンドリー セラピューティクス， インコーポレイテッド 治療剤の制御放出のための埋込み可能なデポー
US12364792B2 (en) 2018-01-08 2025-07-22 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
KR20210119980A (ko) 2019-01-22 2021-10-06 아크리베스 바이오메디컬 게엠베하 손상된 피부 상처를 치료하기 위한 선택적 글루코코르티코이드 수용체 개질제

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
WO2000000194A1 (en) 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DE60309829T2 (de) * 2002-01-14 2007-09-13 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
KR101022977B1 (ko) 2002-03-26 2011-03-18 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
US6897224B2 (en) 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
MXPA05006872A (es) 2003-01-03 2005-08-16 Boehringer Ingelheim Pharma Derivados de 1-propanol y 1-propilamina y su uso como ligandos glucocorticoides.
US20040224992A1 (en) 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004097410A1 (en) 2003-04-30 2004-11-11 Pfizer Products Inc. Screening methods for cataractogenic risk
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
CA2558019A1 (en) 2004-03-22 2005-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
DE102004055633A1 (de) 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7417056B2 (en) 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
CN102304124B (zh) 2005-09-14 2014-10-22 参天制药株式会社 具有糖皮质激素受体结合活性的1,2-二氢喹啉衍生物
WO2008146871A1 (ja) 2007-05-29 2008-12-04 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
US20120065228A1 (en) * 2007-08-10 2012-03-15 Jinzhong Zhang Compositions and methods for treating, controlling, reducing, or ameliorating ocular inflammatory with lower risk of increased intraocular pressure
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US20110281882A1 (en) * 2007-08-10 2011-11-17 Jinzhong Zhang Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain

Also Published As

Publication number Publication date
AR086686A1 (es) 2014-01-15
KR20140035481A (ko) 2014-03-21
AU2012268692A1 (en) 2014-01-16
TW201300378A (zh) 2013-01-01
WO2012170175A1 (en) 2012-12-13
CA2838876A1 (en) 2012-12-13
US20120316199A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
MX2013014518A (es) Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
EP3632444A3 (en) Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX2009006526A (es) Metodo para suministrar terapia con pirfenidona a un paciente.
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
HK1215934A1 (zh) 肽治疗剂及其使用方法
WO2011026076A3 (en) Topical formulations comprising a steroid
HK1219661A1 (zh) 用於治疗皮肤病的甲酰基肽受体2的激动剂的用途
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
MX2010005210A (es) Formulacion de aceite de oliva para alivio del dolor.
PL2051710T3 (pl) Kompozycje i sposoby leczenia, zmniejszania, polepszania lub łagodzenia chorób tylnego odcinka oka
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
NZ630471A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
WO2010030976A3 (en) Methods and compositions for inhibiting atherosclerosis and vascular inflammation
MX2009002228A (es) Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.
MX2010001370A (es) Composiciones que comprenden agonista del receptor glucocorticoide disociado para tratar o controlar inflamacion del segmento anterior.
PT2061444E (pt) Composições e métodos de tratamento, controlo, redução, melhoramento ou prevenção de alergias
PH12022552358A1 (en) Oligosaccharide formulations of kappa opioid receptor agonists
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.